Sarcopenic Obesity, Insulin Resistance, and Their Implications in Cardiovascular and Metabolic Consequences
Open accessThe DOI matches its Crossref record; 153 of the 153 references it cites were found in a registry or an index; 26 of the 102 sources its claims cite were checked for support.
Abstract
The prevalence of sarcopenic obesity is increasing worldwide, particularly amongst aging populations. Insulin resistance is the core mechanism of sarcopenic obesity and is also associated with variable cardiometabolic diseases such as cardiovascular disease, type 2 diabetes mellitus, and non-alcoholic fatty liver disease. Fat accumulation in muscle tissue promotes a proinflammatory cascade and oxidative stress, leading to mitochondrial dysfunction, impaired insulin signaling, and muscle atrophy. To compound the problem, decreased muscle mass aggravates insulin resistance. In addition, the crosstalk between myokines and adipokines leads to negative feedback, which in turn aggravates sarcopenic obesity and insulin resistance. In this review, we focus on the molecular mechanisms linking sarcopenic obesity and insulin resistance with various biological pathways. We also discuss the impact and mechanism of sarcopenic obesity and insulin resistance on cardiometabolic disease.
Overview
CoChat Summary
TL;DR
This narrative review argues that insulin resistance is the core mechanism linking sarcopenic obesity to cardiometabolic disease through fat accumulation, inflammation, mitochondrial dysfunction, and impaired insulin signaling in skeletal muscle. It further discusses how myokine–adipokine crosstalk and hormonal changes aggravate sarcopenic obesity and its cardiovascular, metabolic, and hepatic consequences.
Key findings
- Sarcopenic obesity is associated with a 2–3 times higher risk of functional disability than either sarcopenia or obesity alone, and it combines muscle loss with fat accumulation, including intramyocellular lipid, intermyocellular adipose tissue, and peri-muscular adipose tissue.
- In skeletal muscle, lipid intermediates such as DAG and ceramides activate PKC, JNK, IKK/NF-kB, and related pathways, causing serine/threonine phosphorylation of insulin receptor/IRS-1, impaired PI3K/Akt signaling, and reduced GLUT4 translocation; this impairs glucose uptake and promotes muscle atrophy.
- Inflammation is central: adipose tissue macrophage staining is approximately 10% in lean subjects but up to 50% in obese subjects, and proinflammatory cytokines such as TNF-α, IL-1β, and IL-6 contribute to insulin resistance, muscle atrophy, and cardiometabolic disease.
- Sarcopenic obesity and insulin resistance are linked clinically to atherosclerosis/cardiovascular disease, chronic heart failure, type 2 diabetes mellitus, metabolic syndrome, and NAFLD; skeletal muscle accounts for approximately 80–90% of postprandial glucose uptake, making muscle insulin resistance crucial in diabetes pathogenesis.
Methods
- Design: narrative review of molecular and clinical literature on sarcopenic obesity, insulin resistance, and cardiometabolic disease.
- Data/sample: no primary cohort or experimental sample; the paper synthesizes prior human, animal, and in vitro studies and cites clinical examples, including studies on carotid intima-media thickness, myocardial infarction, chronic heart failure, type 2 diabetes, metabolic syndrome, and NAFLD.
- Main analysis: thematic synthesis of mechanisms, including fat accumulation, inflammation, sex/growth hormone deficiency, skeletal muscle insulin signaling pathways, myocyte–adipocyte crosstalk, and pathophysiological links to cardiometabolic diseases.
Limitations
- The paper states that the definition of sarcopenic obesity has not been universally established and that different diagnostic criteria have different clinical implications.
- The paper repeatedly notes conflicting or insufficient evidence, including controversy over irisin and exercise, adiponectin’s clinical role, JAK/STAT signaling in muscle insulin resistance, and whether obesity itself is more predictive than sarcopenia for metabolic syndrome in some studies.
- Evident from the text: as a narrative review without a stated systematic search strategy, risk-of-bias assessment, or meta-analysis, it cannot quantify effect sizes or resolve heterogeneity across the cited studies.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
20 Valid · 4 Not valid · 62 Not checked · 9 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“A British regional health study reported that older subjects with sarcopenic obesity had the highest cardiovascular mortality [113].”
§ Sarcopenic Obesity, Insulin Resistance, and Their Implications in Cardiovascular and Metabolic Consequences > 4. Pathophysiological Link among Cardiometabolic Disease, Sarcopenic Obesity, and Insulin Resistance > 4.1. Atherosclerosis and Cardiovascular Disease
What the sources say
- Disputedcites [113] Atkins, 2014, Sarcopenic obesity and risk of cardiovascular disease and mortality: A population-based cohort study of older men, J. Am. Geriatr. Soc. sourceExperimental — accuracy not yet measured
Our copy (Abstract Conclusion; Discussion, and Discussion > Strengths and Limitations) states the opposite for cardiovascular mortality: 'Sarcopenic obese men had the highest risk of all-cause mortality but not CVD mortality,' and the Abstract Results add that CVD mortality risk was significantly greater in sarcopenic and obese but NOT sarcopenic obese men. The only point at which the sarcopenic obese group topped CVD mortality was the age-adjusted model, which lost significance after adjustment for lifestyle variables (Results). The highest-risk finding the paper reports for sarcopenic obesity is all-cause mortality (HR = 1.72, 95% CI = 1.35–2.18), so the claim substitutes CVD mortality for all-cause mortality; it also generalises 'older men' (British Regional Heart Study, aged 60–79) to 'older subjects'. (LLM, conf=0.85)
Checked by a reasoning model — may be wrong.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This complex disorder results in a 2–3 times higher risk of functional disability than either sarcopenia or obesity alone [14].”
§ Sarcopenic Obesity, Insulin Resistance, and Their Implications in Cardiovascular and Metabolic Consequences > 2. Sarcopenia and Sarcopenic Obesity > 2.1. Definition
What the sources say
- Partly supportedcites [14] Rolland, 2009, Difficulties with physical function associated with obesity, sarcopenia, and sarcopenic-obesity in community-dwelling elderly women: The EPIDOS (EPIDemiologie de l’OSteoporose) Study, Am. J. Clin. Nutr. sourceExperimental — accuracy not yet measured
The Results (page unavailable) report roughly 2–3 times higher odds of difficulty with several physical tasks for sarcopenic-obese women than for purely sarcopenic women. Compared with purely obese women, however, the difference was statistically significant only for going down stairs. The study measured self-reported functional difficulties in a cross-sectional sample, not a general 2–3-fold higher risk of developing disability than either group. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Intermyocellular adipose tissue (IMAT) and IMCL secrete myostatin, CCL2, TNF-α, IL-1β, and IL-6, thus inducing IR and lipotoxicity, which is discussed in the next section [30].”
§ Sarcopenic Obesity, Insulin Resistance, and Their Implications in Cardiovascular and Metabolic Consequences > 2. Sarcopenia and Sarcopenic Obesity > 2.2. Molecular Mechanism of Sarcopenic Obesity
What the sources say
- Partly supportedcites [30] Rivas, 2016, Diminished anabolic signaling response to insulin induced by intramuscular lipid accumulation is associated with inflammation in aging but not obesity, Am. J. Physiol. Regul. Integr. Comp. Physiol. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) links lipid accumulation in obesity to inflammation and secretion of TNF-α, IL-1β, and IL-6. It does not say that IMAT and IMCL themselves secrete those cytokines or myostatin and CCL2, nor does it establish that such secretion induces insulin resistance and lipotoxicity. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The amount of PMAT is correlated with the severity of muscle atrophy [31].”
§ Sarcopenic Obesity, Insulin Resistance, and Their Implications in Cardiovascular and Metabolic Consequences > 2. Sarcopenia and Sarcopenic Obesity > 2.2. Molecular Mechanism of Sarcopenic Obesity
What the sources say
- Supportedcites [31] Zhu, S., Tian, Z., Torigoe, D., Zhao, J., Xie, P., Sugizaki, T., Sato, M., Horiguchi, H., Terada, K., and Kadomatsu, T. (2019). Aging-and obesity-related peri-muscular adipose tissue accelerates muscle atrophy. PLoS ONE, 14. source
The Results section, “PMAT accumulation increases with muscle atrophy in aged mice,” reports that mice with at least 5% PMAT had lower muscle mass and muscle-fiber cross-sectional area than mice with less than 5% PMAT. The authors describe the degree of PMAT deposition as associated with progression of muscle atrophy in aged mice. (LLM, conf=0.92)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Low GH levels reduce IGF1 action by sequentially downregulating the PI3K-AKT/PKB-mTOR pathway, which induces protein synthesis in muscles [49].”
§ Sarcopenic Obesity, Insulin Resistance, and Their Implications in Cardiovascular and Metabolic Consequences > 2. Sarcopenia and Sarcopenic Obesity > 2.2. Molecular Mechanism of Sarcopenic Obesity
What the sources say
- Partly supportedcites [49] Egerman, 2014, Signaling pathways controlling skeletal muscle mass, Crit. Rev. Biochem. Mol. Biol. sourceExperimental — accuracy not yet measured
The section on IGF1/PI3K/Akt hypertrophy signaling (page not provided) describes IGF1 activating PI3K/Akt and mTORC1 signaling in skeletal muscle; its Figure 1 caption links that signaling to protein synthesis. The passages do not say that low growth hormone (GH) levels reduce IGF1 action or downregulate this pathway. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
43 more claims · 9 with their cited sources checked
Create a free account to see all 95 claims and to verify the 76 references still open.
- It may state two separate claims as one. 44
- Probably not a substantial claim. 5
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Various myokines released from active muscles act as signalling mediators between skeletal muscle and other vital organs, such as the liver, fat, and brain.[ 5 ]”
From Pathogenesis of sarcopenia and the relationship with fat mass: descriptive review (2022) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Secondly, metabolic disorders including cardiometabolic syndrome (CMS), diabetes, cardiovascular disease (CVD), and cancer are common comorbidities of SO (54, 55).”
From Diabetes and Sarcopenic Obesity: Pathogenesis, Diagnosis, and Treatments (2020) · cites this paper as [54]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Obesity can independently lead to loss of muscle mass and function, due to the negative impact of adipose tissue-dependent metabolic derangements, such as oxidative stress, in fl ammation, and insulin resistance, all which negatively affect muscle mass [6].”
From Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement (2022) · cites this paper as [6]
In the citing paper
“Aging-associated increases in visceral fat and reduced muscle mass are correlated with multiple adverse cardiometabolic effects and contribute to poor health outcomes (119).”
From Health Consequences of Sarcopenic Obesity: A Narrative Review (2020) · cites this paper as [119]
In the citing paper
“Obesity can independently lead to loss of muscle mass and function, due to the negative impact of adipose tissue-dependent metabolic derangements, such as oxidative stress, inflammation and insulin resistance, all of which negatively affect muscle mass [6].”
From Definition and Diagnostic Criteria for Sarcopenic Obesity: ESPEN and EASO Consensus Statement (2022) · cites this paper as [6]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Sarcopenia: revised European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afy169 · Cited by 13,818
Obesity is associated with macrophage accumulation in adipose tissue
Weisberg, S. P., McCann, D., Desai, M., Rosenbaum, M., Leibel, R. L., & Ferrante, A. W. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200319246 · Cited by 10,041
Inflammation, Atherosclerosis, and Coronary Artery Disease
Hansson, G. K. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043430 · Cited by 8,773 · cited 1×
“Atherogenesis is a complicated process that includes oxidative stress, inflammation, endothelial dysfunction, vascular proliferation, and thrombosis [104].”
BackgroundIncreased oxidative stress in obesity and its impact on metabolic syndrome
Furukawa, S., Fujita, T., Shimabukuro, M., Iwaki, M., Yamada, Y., Nakajima, Y., Nakayama, O., Makishima, M., Matsuda, M., & Shimomura, I. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21625 · Cited by 5,508 · cited 2×
“It causes the dysregulation of adipocytokines, such as adiponectin, PAI-1, IL-6, and MCP-1, leading to metabolic syndrome [134].”
BackgroundA PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis
Boström, P., Wu, J., Jedrychowski, M. P., Korde, A., Ye, L., Lo, J. C., Rasbach, K. A., Boström, E. A., Choi, J. H., Long, J. Z., et al. (2012) · Nature · doi:10.1038/nature10777 · Cited by 4,810 · cited 1×
“Irisin is a PPARγ-coactivator-1α (PGCα)-dependent myokine that stimulates browning in subcutaneous adipose tissues and induces increased energy expenditure, which improves obesity and IR through the MAPK and ERK pathways [92,93].”
BackgroundYamauchi, T., Kamon, J., Minokoshi, Y., Ito, Y., Waki, H., Uchida, S., Yamashita, S., Noda, M., Kita, S., Ueki, K., et al. (2002) · Nature Medicine · doi:10.1038/nm788 · Cited by 4,238
Sarcopenia in Asia: Consensus Report of the Asian Working Group for Sarcopenia
Chen, L.-K., Liu, L.-K., Woo, J., Assantachai, P., Auyeung, T.-W., Bahyah, K. S., Chou, M.-Y., Chen, L.-Y., Hsu, P.-S., Krairit, O., et al. (2014) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2013.11.025 · Cited by 4,051 · cited 3×
“Sarcopenia results in a decreased metabolic rate, low physical activity, and myokine deficiency, which collectively leads to the proinflammatory effect, and exacerbates obesity.”
BackgroundInfluentialSarcopenia: revised European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afz046 · Cited by 3,803
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604
A Novel Paradigm for Heart Failure With Preserved Ejection Fraction
Paulus, W. J., & Tschöpe, C. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.02.092 · Cited by 3,564 · cited 1×
“Inflammation due to sarcopenic obesity results in reduced NO, cyclic guanosine monophosphate (cGMP), and protein kinase G (PKG) activity in cardiomyocytes, leading to LV hypertrophy and stiffness [120].”
Background
Research works printed but not linked: 1
- White, 2013, Knockout of STAT3 in skeletal muscle does not enhance insulin action, Diabetologia, 56, S250
Cited by
Definition and Diagnostic Criteria for Sarcopenic Obesity: ESPEN and EASO Consensus Statement
Donini, L. M., Busetto, L., Bischoff, S. C., Cederholm, T., Ballesteros-Pomar, M. D., Batsis, J. A., Bauer, J. M., Boirie, Y., Cruz-Jentoft, A. J., Dicker, D., et al. (2022) · Obesity Facts · doi:10.1159/000521241 · Cited by 1,019
The crucial role and mechanism of insulin resistance in metabolic disease
Zhao, X., An, X., Yang, C., Sun, W., Ji, H., & Lian, F. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1149239 · Cited by 557
Tanase, D. M., Gosav, E. M., Costea, C. F., Ciocoiu, M., Lacatusu, C. M., Maranduca, M. A., Ouatu, A., & Floria, M. (2020) · Journal of Diabetes Research · doi:10.1155/2020/3920196 · Cited by 627
“Hence, IR and inflammation form a vicious circle, each condition promoting the other and accelerating the development of NAFLD and other metabolic disorders in the presence of lipotoxicity [107].”
BackgroundPathogenesis of sarcopenia and the relationship with fat mass: descriptive review
Li, C., Yu, K., Shyh‐Chang, N., Jiang, Z., Liu, T., Ma, S., Luo, L., Guang, L., Liang, K., Ma, W., et al. (2022) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12901 · Cited by 626
Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement
Donini, L. M., Busetto, L., Bischoff, S. C., Cederholm, T., Ballesteros-Pomar, M. D., Batsis, J. A., Bauer, J. M., Boirie, Y., Cruz-Jentoft, A. J., Dicker, D., et al. (2022) · Clinical Nutrition · doi:10.1016/j.clnu.2021.11.014 · Cited by 566
“Obesity can independently lead to loss of muscle mass and function, due to the negative impact of adipose tissue-depen-dent metabolic derangements, such as oxidative stress, inflammation and insulin resistance, all of which negatively affect muscle mass [6].”
Metadata
- Authors
- Hong, S.-H., & Choi, K. M.
- Affiliations
- Korea University (KR)
- Corresponding author
- Choi, Kyung Mook
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2020-01-13
- Volume
- 21
- Issue
- 2
- Pages
- 494
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC7013734
- OpenAlex
- W2999215393
- Cited by
- 390
- References
- 153
- Citations by year
- 2026: 91 · 2025: 87 · 2024: 68 · 2023: 72 · 2022: 40 · 2021: 20 · 2020: 11
- FWCI
- 4.59
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Korea Christian University (Q1625561)
- Topics
- Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
- Keywords
- sarcopenic obesity, insulin resistance, cardiometabolic disease, type 2 diabetes, non-alcoholic fatty liver disease, cardiovascular disease, muscle atrophy, mitochondrial dysfunction, oxidative stress, myokines, adipokines, insulin signaling, aging
- MeSH terms
- Animals, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Humans, Insulin Resistance, Mitochondria, Liver, Mitochondria, Muscle, Obesity, Sarcopenia, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sarcopenic Obesity, Insulin Resistance, and Their Implications in Cardiovascular and Metabolic Consequences. https://app.cochat.ai/papers/10.3390/ijms21020494
- The paper
- Hong, S.-H., & Choi, K. M. (2020). Sarcopenic Obesity, Insulin Resistance, and Their Implications in Cardiovascular and Metabolic Consequences. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms21020494
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.